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Abstract: Fe3O4 particles are currently used as the core of immunomagnetic microspheres 
in the immunomagnetic enrichment assay of circulating tumor cells (CTCs). It is difficult to 
further improve the sensitivity of CTC detection or to improve tumor cell-type identification 
and characterization. In the present study, we prepared immunomagnetic nanoparticles with 
nanopure iron as the core, coated with anti-cytokeratin 7/8 (CK7/8) monoclonal antibody. These 
immunomagnetic nanoparticles (IMPs) were used in conjunction with immunocytochemistry 
(ICC) to establish a refined immunomagnetic nanoparticle enrichment assay for CTC detection in 
non-small cell lung cancer (NSCLC). The assay was compared with nested reverse transcription 
polymerase chain reaction (RT-PCR) to detect CK19 mRNA and lung specific X protein (LUNX) 
mRNA. Human lung adenocarcinoma cell line A549 was used for sensitivity and specificity 
evaluation. Peripheral blood samples were collected from each group for CTC detection. The 
average diameter of the immunomagnetic nanoparticles was 51 nm, and the amount of adsorbed 
antibodies was 111.2 µg/mg. We could detect down to one tumor cell in 5 × 107 peripheral 
blood mononuclear cells. The sensitivity was consistent with that of nested RT-PCR; however, 
the false positive rate was significantly reduced. The modified assay combined with ICC did 
not differ from nested RT-PCR in sensitivity, but it had significantly increased specificity. This 
approach could, therefore, contribute to identification of micrometastases, re-defining clinical 
staging, and guiding individual postoperative treatments. The technique shows considerable 
potential clinical value and further clinical trials are warranted.
Keywords: NSCLC, circulating tumor cells, nested RT-PCR, immunomagnetic nanoparticles, 
immunocytochemistry
Introduction
Lung cancer is one of the most threatening malignant tumors in humans. The overall 
5-year survival rate for all persons diagnosed with lung cancer is only 13% (47% for 
focal lesion patients, 17% for regional spread patients, and 1.7% for distant metastasis 
patients).1 Non-small cell lung cancer (NSCLC) accounts for 80% of primary lung 
cancers, which are treated with surgery. However, lung cancer metastasis has already 
occurred in 65% of NSCLC patients at diagnosis, when it is too late for surgical 
treatment.2 Even when patients with stage I or II NSCLC have the opportunity to 
receive surgical treatment, the prognosis is poor, often with local recurrence and 
distant metastasis.3
Tumor metastasis is the spread of malignant tumor cells from primary lesions to 
secondary tissues or organs through various proliferation and growth mechanisms 
leading to the formation of secondary tumors. It is a multi-stage and multi-step process 
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characterized by spread in the blood and lymph. Kotlyarov 
et al4 reported that the focal recurrence rate was 33.8%, 
and the rate of blood-born metastasis was 55.2% during 
the 10 years after radical resection. Of the recurrences, 
69.4% of focal recurrence and 88.7% of blood-born 
metastasis occurred within 1 year after surgery.4 However, 
no dominant metastases were found in patients undergo-
ing preoperative or postoperative routine examinations, 
including surgical exploration, B ultrasound, computed 
tomography (CT), magnetic resonance imaging (MRI), or 
emission computed tomography (ECT). Therefore, micro-
metastasis occurring in the blood, bone marrow, lymph 
nodes, and other   tissues and organs may be the origin of 
tumor recurrence and metastasis. It has been verified that 
the 5-year survival rate for micrometastasis patients is very 
low, with unfavorable prognosis.5 It is therefore of great 
importance for clinical diagnosis, treatment, and prognostic 
prediction to accurately determine the occurrence and range 
of micrometastasis.
CTC detection could become a valuable tool for early-stage 
cancer diagnosis and could serve as a real-time tumor biopsy 
to assess tumor invasion. Common technologies for NSCLC 
metastasis detection include reverse transcription polymerase 
chain reaction (RT-PCR) and immunocytochemistry (ICC). 
RT-PCR has a higher sensitivity but a higher false positive 
rate. ICC is regarded as having greater specificity, but it can 
only detect down to a sample size of 5 × 105 cells, although 
an ideal cell sample size is 2.5 × 108. As previously described, 
simple ICC technology cannot detect circulating tumor cells 
(CTCs) in NSCLC patients.6
Immunomagnetic nanoparticle enrichment is an 
advanced tool for tumor diagnosis, and immunomagnetic 
nanoparticles are characterized by their high specificity, 
ability to form high-concentration suspensions, high 
separation rates, and lack of influence on cell activity. It has 
been reported that CTC separation rates can be improved 
103–104 times by using this technology.7 In the present study, 
we prepared new modified immunomagnetic nanoparticles 
with nanopure iron as the core. We coated these nano-
particles with anti-cytokeratin 7/8 (CK7/8) monoclonal 
antibody and, in combination with ICC technology, we 
detected peripheral blood CTCs in NSCLC patients. Using 
this combined technology, we could isolate one tumor cell 
from 5 × 107 cells. This could contribute to the discovery 
of early micrometastases, monitoring of tumor recurrence 
and metastasis, prognosis evaluation, and preparation of 
individual postoperative treatments.
Materials and methods
Preparation of immunomagnetic 
nanoparticles
Sodium alginate (100 mg, Sigma-Aldrich, St Louis, MO) 
was dissolved into 4 mL water and 2 mL of 5% pure Fe 
magnetic fluid solution was then added (average diameter: 
10 nm ± 5 nm, purity: 99.99%, specific saturation magne-
tization $1800 Am2/kg, intrinsic coercivity $ 34.8 KA/m, 
provided by Shenzhen Junye Nano Material Ltd, Shen-
zhen, China). The solution was mixed thoroughly at 
42°C and then underwent 15 minutes of  ultrasound irradia-
tion. 10% Na2CO3 was added to adjust the pH to 10, and the 
mixture was heated to 60°C. Under ultrasound irradiation 
and high-speed mixing, the mixture was dripped into 90 mL 
di-2-ethylhexyl sulfosuccinate (AOT, Sigma-Aldrich)/
heptane oil at 60°C to form a transparent gray-black reverse 
microemulsion system. Following addition of 4.5 mL 30% 
CaCl2, the microemulsion system was subjected to immuno-
magnetic separation. Following washing with acetone, etha-
nol, and distilled water, 1500 rpm centrifugal separation was 
performed and samples vacuum freeze-dried for storage.
After rinsing three times with phosphate buffer solution 
(PBS), 1 mg of prepared nanoparticles was immersed in 
4 mL of 0.01 mol/L PBS (pH = 7.0), and 5 mg carbodiimide 
(EDC, Sigma-Aldrich) and 7.5 mg sulfo-N-hydroxysuccin-
imide (sulfo-NHS, Sigma-Aldrich) were added and mixed 
thoroughly. After 15 minutes at room temperature, 50 mg 
6-aminocaproic acid was added and the mixture was mixed 
for 3 hours, after which 600 µL of 30 µg/mL cytokeratin 
7/8 (CK7/8) monoclonal antibody (Chemicon, Temecula, 
CA) was then added and mixed for 6 hours. The mixture 
was then sealed with 1 mL of 0.2 mol/L glycine solution 
containing 0.2% bovine serum albumin (BSA). The mix-
ture was preserved at 4°C followed by magnetic separation 
and addition of storage solution. Transmission electron 
microscopy (TEM, TECHAI-10; Phillips, Amsterdam, the 
Netherlands) and light microscopy (TE2000-U; Nikon, 
Tokyo, Japan) were used for qualitative determination of 
nanoparticle morphology.
Clinical specimens
Fifty-five patients with primary NSCLC admitted to our 
hospital between March 2010 and May 2011 were enrolled 
in this study, including 30 males and 25 females, aged 
43–75 years with an average age of 57.6 years. The grades 
were as follows: 21 stage I cases, comprising 13 squamous 
cell lung carcinoma cases and eight lung adenocarcinoma 
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cases; 21 stage II cases, comprising 13 squamous cell lung 
carcinoma cases and eight lung adenocarcinoma cases; ten 
stage III cases, comprising six squamous cell lung carcinoma 
cases and four lung adenocarcinoma cases; three stage IV 
cases, comprising one squamous cell lung carcinoma case 
and two lung adenocarcinoma cases. The 55 patients were 
confirmed to have NSCLC after surgical inspection, and 
NSCLC was staged using the Tumor, Node, Metastasis 
(TNM) system.8 All patients were diagnosed primarily with-
out history of other epithelial tumors and infectious diseases. 
Another 25 patients with benign lung diseases (BLD) were 
enrolled, including tuberculoma in six cases, inflammatory 
pseudotumor in two cases, and bronchiectasis disease in six 
cases. There were 14 males and 11 females. The age range 
was 32–67 years, with a mean age of 53.4 years. Twenty-five 
healthy volunteers (13 males and 12 females with a mean age 
of 39.6 years, ranging 28–60 years) served as controls. There 
were four groups in the study: group A, stage I NSCLC; group 
B, stage II–IV NSCLC; group C, benign lung disease patients; 
group D, healthy volunteers. All samples were collected and 
analyzed after obtaining written informed consent.
Experimental methods
The sensitivity of immunomagnetic  
nanoparticles to CTCs
Two hundred milliliters of peripheral blood were collected 
from healthy volunteers. Following heparin anticoagulation 
(BD Vacutainer; Becton Dickinson, Franklin Lakes, NJ), 
blood specimens were processed by density gradient sepa-
ration. Peripheral blood mononuclear cells (PBMCs) were 
isolated and counted after rinsing twice with PBS. Human 
lung adenocarcinoma A549 cells were added to PBMC suspen-
sions to give ratios of PBMCs to A549 cells of 104:1, 105:1, 
106:1, 5 × 106:1, 1 × 107:1, 5 × 107:1 and 1 × 108:1. Twenty 
microliters of immunomagnetic nanoparticles were added to 
each specimen. The suspension was mixed for 30 minutes at 
room temperature, and then separated using a magnetic separa-
tor. Enriched tumor cell suspensions were coated onto slides, the 
slides were air-dried and detected by immunocytochemistry 
(ICC). The tumor cells were detected with an anticytokeratin 
antibody directed against cytokeratins 7 and 8, as described 
previously.9 Labeled cells were detected with biotinylated 
goat anti-rabbit IgG and streptavidin horseradish peroxidase. 
The streptavidin-peroxidase method was routinely used.9
The procedures described were repeated five times 
for each concentration. Slides were evaluated by light 
microscopy (40× objective), and tumor cells were evaluated 
by an experienced pathologist. Tumor cells with red cytoplasm 
were CK-positive cells. CK-positive cells were then observed 
under the 100× oil-immersion objective to identify nuclear 
specificity and nucleoli and chromatin changes to differenti-
ate tumor cells. The tumor cell recovery rate in enriched cells 
was calculated. The experiment was repeated on a subsequent 
day. Scanning electron microscopy was also conducted.
Ten milliliters of blood were obtained from all patients. 
Following heparin anticoagulation (BD Vacutainer; 
  Becton Dickinson, Franklin Lakes, NJ), the blood samples 
were subjected to a red cell lysis step to isolate PBMCs. 
The isolated PBMCs were split into two aliquots for 
  detection of CK19 mRNA and LUNX mRNA: one using 
nano-immunomagnetic separation plus ICC, and simple ICC, 
the other using nested RT-PCR.
Immunomagnetic nanoparticles enrichment  
assay for CTC detection
The isolated PBMCs were placed in a 15 mL flask followed 
by the addition of 20 µL immunomagnetic nanoparticles. 
The mixture was rotated and mixed for 30 minutes at room 
temperature and then separated using a magnetic separator. 
Enriched cell suspension samples were selected using the 
dropping method. CTC staining and result determination were 
performed using the previously described ICC method.
Total RNA extraction and nested RT-PCR
Total RNA extraction was performed according to 
the TrezolTM RNA Isolation Reagent kit manual (Gibco 
Laboratories, Lawrence, MA). We checked RNA quality 
by separating 5 µL total RNA by electrophoresis and 
observing the 18S and 28S RNA bands. RNA was 
quantified spectrophotometrically using the formula: RNA 
(µg/µL) = A260 × 40 × dilution/1000. CK19 mRNA and 
LUNX mRNA PCR primer sequences were designed 
according to the literature.10,11 Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) primers were designed with DNA 
analysis software (Table 1). All primers were manufactured 
by Sangon Biotech (Shanghai, China). To test for sensitivity 
of nested RT-PCR, isolated PBMCs from healthy volunteers 
were combined with A549 cells in equal proportions for total 
RNA extraction. For nested RT-PCR detection, experimental 
procedures were performed according to the instructions 
of an RT-PCR kit (BioDev-Tech, Beijing, China). The RT 
reaction system was 20 µL, and reaction conditions were 
37°C for 2 hours and 95°C for 5 minutes. Two rounds 
of PCR were performed under the same conditions: after 
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denaturation at 94°C for 5 minutes, 35 cycles consisting 
of 94°C for 45 seconds, 58°C for 30 seconds, and 72°C 
for 60 seconds were performed, with a final extension step 
at 72°C for 8 minutes. Five microliters of PCR product 
from the second round was separated by 1.5% agarose gel 
electrophoresis, stained with ethidium bromide (EB), and 
observed using an Image Acquisition and Analysis System 
(Bio-Rad, Hercules, CA) with a directed image camera 
(Olympus, Tokyo, Japan).
Statistical analysis
SPSS software (v 13.0; IBM, Armonk, NY) was used for 
the statistical analysis of all data. Detection results were 
expressed as χ –
 ± s. The Chi-square test was used to compare 
enumeration data. Results were considered to be statistically 
significant at P , 0.05.
Results
Morphology and diameter  
of immunomagnetic nanoparticles
When viewed under a transmission electron microscope, the 
immunomagnetic nanoparticles were of regular spherical 
shape, showed good dispersion properties and had a mean 
diameter of 51 nm (range 35–80 nm, Figure 1). Protein 
concentration on the immunomagnetic nanoparticles was 
measured by the Bradford method. One milligram of immu-
nomagnetic nanoparticles could bind 111.2 µg of antibodies. 
Flow cytometry showed that 98.8% of immunomagnetic 
nanoparticles were coated with CK7/8 antibodies.
Sensitivity of immunomagnetic 
nanoparticles to CTCs
The experiment was repeated five times for each concentration 
ratio of PBMCs to A549 cells and the results showed that 
no CTCs were detected at a concentration ratio of 1 × 108:1; 
CTCs were detected once and twice, respectively, at the 
ratios of 5 × 107:1 and 1 × 107:1. CTCs were detected in 
all five experiments at the ratios of 104:1, 105:1, 106:1, and 
5 × 106:1. The recovery tests, performed at two different 
times, gave a tumor cell recovery rate with immunomagnetic 
cell enrichment ranging from 86% to 93%. One tumor cell 
in 107 peripheral blood mononuclear cells can be detected as 
positive, with a specificity of 100%. After immunomagnetic 
nanoparticle enrichment and ICC, cells with red cytoplasm 
were identified as tumor cells (Figure 2A). Scanning electron 
microscopy showed that there were numerous immunomag-
netic nanoparticles present on the surface of enriched tumor 
cells (Figure 2B). A high magnification image shows many 
nanoparticles adhered to the cell membrane (Figure 2C).
Detection of CTCs in NSCLC patients 
using immunomagnetic nanoparticle 
separation
Using immunomagnetic nanoparticle enrichment and ICC, 
CK-positive cells were found in seven of 21 stage I NSCLC 
patients, while there were no CK-positive cells detected using 
Table 1 The sequences of CK19, LUNX, and GAPDH primers
Primers Sequences of primers Product size
CK19 5′-AAGCTAACCATGCAGAACCTCAACGACCGC-3′
Out primer 5′-TTATTGGCAGGTCAGGAGAAGAGCC-3′ 1069 bp
CK19 5′-TCCCGCGACTACAGCCACTACTACACGACC-3′
Inner primer 5′-CGCGACTTGATGTCCATGAGCCGCTGGTAC-3′ 745 bp
LUNX 5′-GGGCCTCATTGTCTTCTACGGG-3′
Out primer 5′-GAATGGGTGCAGTCACCAAGGAC-3′ 534 bp
LUNX 5′-CTCATTGTCTTCTACGGGCTGTTAG-3′
Inner primer 5′-CTTTATGCCGAGAGGGATGGT-3′ 396 bp
GAPDH 5′-TCCATGACAACTTTGGTATC-3′
5′-TTCAGCTCAGGGATGACCTTG-3′ 183 bp
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LUNX, lung specific X protein; CK, cytokeratin; bp, base pairs.
Figure 1 Transmission electron microscopy picture of immunomagnetic nanoparticles.
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simple ICC. Of the 34 stage II–IV patients, CK-positive 
cells were detected in 22 patients by immunomagnetic 
nanoparticles enrichment and ICC, while, again, there were 
no CK-positive cells detected by simple ICC. CK-positive 
cells were not found in 25 benign lung disease patients and 
25 healthy volunteers using immunomagnetic nanoparticle 
(IMP) enrichment and ICC or simple ICC (Table 2).
Nested RT-PCR detection
Sensitivity results
Following amplification using nested RT-PCR, expression of 
CK19 mRNA and hMAM mRNA was detected in the sample 
at the ratio of 1 × 107:1, indicating that the lowest detectable 
concentration was 1 × 107:1.
Detection of CTCs
Using nested RT-PCR, GAPDH was found in all 55 NSCLC 
patients. Of the 21 stage I NSCLC patients, CK19 mRNA 
expression was detected in seven patients and LUNX mRNA 
expression was detected in eight patients. Of the 34 stage II–IV 
NSCLC patients, CK19 mRNA expression was detected in 
22 patients, and LUNX mRNA expression was detected in 
23 patients (Figure 3A and B). Of the 25 benign lung patients, 
six patients had detectable CK19 mRNA expression and 
five had detectable LUNX mRNA expression. No CK19 or 
LUNX expression was found in the 25 healthy volunteers 
(Table 2).
Association between the CTC positive rate  
and pathological features of NSCLC
Age, sex, and smoking were not influential factors (P . 0.05), 
but pathological types of lung cancer, degree of cell differ-
entiation, and clinical staging were significantly related to 
the CTC detection rate using the modified immunomagnetic 
nanoparticle enrichment assay (P , 0.05, Table 3).
Discussion
There is currently no valid therapy for NSCLC metastasis 
and postoperative recurrence. Early diagnosis of tumor 
micrometastasis and recurrence responses to targeted 
therapies can prolong the tumor-free survival period of 
NSCLC patients. However, the detection of tumor micro-
metastasis is   difficult using conventional histopathology 
methods, leading to delays in treatment. Recent studies have 
established that the presence of tumor micrometastasis leads 
to an unfavorable prognosis in NSCLC patients. Osaki et al 
performed ICC testing in 115 cases of stage I NSCLC to 
detect reactivity to AE1/AE3 anti-CK monoclonal antibodies 
in 2435 hilar and mediastinal lymph nodes. Univariate and 
multivariate analysis showed that tumor micrometastasis 
in lymph nodes is a marker for poor prognosis (P = 0.008; 
P = 0.01).1 Yamashita et al reported that 103 patients with 
lung cancer micrometastases in peripheral blood had a shorter 
survival period than the negative group, and multivariate 
analysis showed that micrometastasis in peripheral blood 
Figure 2 Images of A549 cell enrichment by immunomagnetic nanoparticles. (A) The positive enriched cell was stained with ICC; (B) SEM image of many immunomagnetic 
nanoparticles attached to A549 cells; (C) SEM image of immunomagnetic nanoparticles binding to the surface of an A549 cell.
Abbreviations: SEM, scanning electron microscopy; ICC, immunocytochemistry.
Table 2 Comparison of the results of three methods
Group N ICC (%) IMPs + ICC (%) RT-PCR (%) 
CK19 mRNA LUNX mRNA
NSCLC 55 0 29 (52.7%) 29 (52.7%) 31 (56.4%)
Stage I 21 0 7 (33.3%) 7 (33.3%) 8 (38.1%)
Stage II–IV 34 0 22 (64.7%) 22 (64.7%) 23 (67.6%)
BLD 25 0 0 6 (24.0%) 5 (20.0%)
Volunteers 25 0 0 0 0
Abbreviations: NSCLC, non-small cell lung cancer; ICC, immunocytochemistry; IMPs, immunomagnetic particles; BLD, benign lung diseases; RT-PCR, reverse transcription 
polymerase chain reaction; LUNX, lung specific X protein; CK, cytokeratin.
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before surgery is an independent prognostic indicator.12 
Preparation of immunomagnetic nanoparticles and detection 
of micrometastasis can assist in the early detection of lung 
cancer at diagnosis and relapse.
Common technologies for detecting lung cancer microme-
tastasis include immunohistochemistry, flow   cytometry, and 
RT-PCR.13 The immunomagnetic nanoparticle enrichment 
technique used to capture CTCs can facilitate concentrating 
CTCs 103–104 times. Immunomagnetic nanoparticle enrich-
ment combined with ICC and pathology examination provides 
a new method for early diagnosis of NSCLC.14,15 In recent 
years, the continuous development of nanotechnology has 
seen the successful development of iron nanomaterials. We 
used nanopure iron microspheres as the core of immunomag-
netic nanoparticles. Nanopure iron has a strong specific satu-
ration magnetization: 2.4 times that of Fe3O4 (680 Am2/kg). 
Combined with ICC, prepared immunomagnetic nanoparticles 
are superparamagnetic nanoparticles possessing high mag-
netic response speed, good suspension stability, high mono-
dispersity, and a large surface area. This technology overcomes 
some of the deficiencies of traditional magnetic nanoparticles, 
such as insufficient magnetic force, slow magnetic response 
speed, and dissociation after cell enrichment.16
The antibody crosslinked on the surface of  magnetic micro-
spheres usually cannot achieve complete contact between the 
biological macromolecules and ligands as a result of steric 
hindrance, which reduces the space utilization of the ligands. 
Therefore, in this study, we linked a spacer arm of 6-amino 
hexanoic acid with a carbon chain length of 6, covered with 
active groups, to the microspheres. Following coupling to the 
corresponding antibodies using EDC, high quality immuno-
magnetic nanoparticles were successfully prepared.16 There 
were up to 111.2 µg antibodies per mg of immunomagnetic 
nanoparticles, and flow cytometry showed that 98.3% of the 
immunomagnetic nanoparticles possessed immunoactive 
antibodies. The recovery experiment showed that 93% of 
A549 cells could be easily and rapidly recovered using the 
modified immunomagnetic nanoparticles.
Using modified immunomagnetic nanoparticle enrich-
ment and ICC methods, CTCs were detected at the ratio of 
5 × 107:1, indicating that the existence of a single tumor cell 
M12345678 M1234567 8
AB
CK19
GAPDH
LUNX
GAPDH
Figure 3 The expression of CK19 mRNA and LUNX mRNA from PBMCs in NSCLC patients. (A): CK19; (B): LUNX (M: DNA marker: Lane 1: Lung cancer tissues;   
Lane 2: Blank control; Lanes 3-8: NSCLC patients).
Abbreviations: PBMCs, peripheral blood mononuclear cells; NSCLC, non-small cell lung cancer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LUNX, lung specific 
X protein; CK, cytokeratin.
Table 3 The relationships between IMPs + ICC positive rate and 
NSCLC pathology
Clinical features N Positive  
data
Positive  
rate (%)
P value
Age (years) .0.05
 , 55 14 7 50.0
 $ 55 41 22 53.7
Sex .0.05
  Male 30 17 56.7
  Female 25 12 48.0
Smoking histories .0.05
  Yes 31 19 61.3
  No 24 10 41.7
Pathological type ,0.05
  Adenocarcinoma 22 9 40.9
  Squamous carcinoma 33 20 60.6
Polarization degree ,0.05
  Poor 21 16 76.2
  Well + moderate 34 13 38.2
In clinical ,0.05
  Stage I 21 7 33.3
  Stage II–IV 34 22 64.7
Abbreviations: NSCLC, non-small cell lung cancer; ICC, immunocytochemistry; 
IMPs, immunomagnetic particles.
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per mL of peripheral blood could be detected. The recovery 
of A597 cells was 93%, and modified immunomagnetic nano-
particles were shown to have high sensitivity and specificity. 
In this study, immunomagnetic particles were combined with 
cytokeratin 7/8 antibody, which exists in various epithelial 
cells and has been confirmed to be a   specific marker in 
NSCLC.17 No positive results were obtained from the blood 
of 25 healthy volunteers using this technique, indicating a 
specificity of 100%. This was an encouraging result because 
it established that the nanoparticle assay is specific to NSCLC 
cells. Compared with nested RT-PCR, the sensitivity was 
not different, but the false positive rate was significantly 
reduced.
CTCs can be detected in the peripheral blood of patients 
with solid tumors, and CTCs are necessary for tumor 
metastasis. As described above, detection of CTCs could 
become a standard prognostic marker. In addition, CTCs, 
as the “pioneers” of solid tumors, have been considered as a 
new target for anticancer drugs. Therefore, the detection of 
peripheral blood CTCs in NSCLC has important diagnostic, 
prognostic, and therapeutic implications. The technique 
shows considerable potential clinical value and further 
clinical trials are warranted.
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